PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Stone
R M
RM
Dana-Farber Cancer Institute, Boston, MA, USA.
De Angelo
J
J
Galinsky
I
I
Estey
E
E
Klimek
V
V
Grandin
W
W
Lebwohl
D
D
Yap
A
A
Cohen
P
P
Fox
E
E
Neuberg
D
D
Clark
J
J
Gilliland
D G
DG
Griffin
J D
JD
D001752:Blast Crisis; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D051941:fms-Like Tyrosine Kinase 3
D004791:Enzyme Inhibitors; D011518:Proto-Oncogene Proteins; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3; D011493:Protein Kinase C